Fig. 2
From: Epidemiology of systemic sclerosis: a multi-database population-based study in Tuscany (Italy)
Prevalence trend (2008–2017) of the investigated drug classes. Glucocorticoids: methylprednisolone and prednisone; Disease-modifying antirheumatic drugs (DMARDs): azathioprine, cyclophosphamide, ciclosporin, methotrexate, hydroxychloroquine, mycophenolic acid, and rituximab; Calcium Channel Blockers (CCB) dihydropyridine derivatives; ACE inhibitors and ARBs (Angiotensin II Receptor Blockers) (plain and in association with dihydropyridine derivatives); Endothelin Receptor Antagonists (ERA): bosentan, ambrisentan, and macitentan; PDE-5 inhibitors (phosphodiesterase-5 inhibitors): tadalafil, vardenafil, and sildenafil; Prostanoids (prostacyclin analogues): iloprost, epoprostenol, treprostinil